ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543

Its studies are mostly in Lymphoma, Non-Hodgkin · Leukemia, Myeloid, Acute, led by Johnson & Johnson.

Drug pageAnti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 1, since Jun 15, 20223 company-led studies, 3 open or runningNext primary completion: Jan 19, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson33 open or runningphase 1since Jun 15, 2022Jun 15, 2022Jan 19, 2028phase 1 · NCT06788509

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 15, 2022First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05424822 · 167 enrolled · United States, Australia, China and more
  2. Oct 25, 2024Phase 1 study in Lymphoma, Non-HodgkinNCT06660563 · 19 enrolled · Australia, Spain, Taiwan and more
  3. Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more

Ahead

  1. Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509

TargetBeta

CD3E →MS4A1 →read by rule
“A fully human effector-silent Fc immunoglobulin G1 (IgG1) trispecific antibody targeting the tumor-associated antigens (TAAs) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29) and cluster of differentiation 20 (CD20), and the T-cell surface antig”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22
GSK5926371GlaxoSmithKlinephase 22
REGN9220ruleRegeneron Pharmaceuticalsphase 21

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more1By invitationJan 19, 2028120
NCT06660563Lymphoma, Non-Hodgkin · Australia, Spain, Taiwan and more1Active, not recruitingJan 19, 202619
NCT05424822Lymphoma, Non-Hodgkin · United States, Australia, China and more1Active, not recruitingOct 31, 2025167

How it is read

Names in the registry

  • “JNJ-80948543”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.